Tag: chronic kidney disease

1. Stopping renin-angiotensin system inhibition in patients with advanced chronic kidney disease was associated with higher risk of mortality, major cardiovascular events, and lower risk of kidney replacement therapy. Evidence Rating Level: 2 (Good) Studies have shown that renin-angiotensin system inhibitors (RASi) are effective in delaying chronic kidney disease (CKD) progression. Angiotensin-converting enzyme...

1. Stopping renin-angiotensin system inhibition in patients with advanced chronic kidney disease was associated with higher risk of mortality, major cardiovascular events, and lower risk of kidney replacement therapy. Evidence Rating Level: 2 (Good) Studies have shown that renin-angiotensin system inhibitors (RASi) are effective in delaying chronic kidney disease (CKD) progression. Angiotensin-converting...

1. Non-calcium-based phosphate binders did not affect arterial stiffness or aortic calcification compared to placebo in moderate-to-severe chronic kidney disease. Evidence Rating Level: 1 (Excellent) Abnormal phosphate homeostasis is characteristic of chronic kidney disease, with hyperphosphatemia strongly associated with increased arterial stiffness secondary to calcification. Positive phosphate balance may contribute to...

1. Patients who underwent Roux-en-Y gastric (RYGB) surgery had higher rates of microalbuminuria remission when compared to those who received only medical treatment at 24 months post-intervention. 2. Patients who underwent RYGB surgery also showed improvements in metabolic control outcomes (HbA1C, LDL-C, triglycerides, and change in total body weight) when...

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study 1. In patients with confirmed SARS-CoV-2 infection within 7 days before or 30 days after surgery, significant mortality was observed, and perioperative pulmonary complications occurred in more than half the patients. Evidence Rating: 2 (Good) Current...

1. The exclusion of patient race from glomerular filtration rate (GFR) estimation resulted in systematic error that significantly underestimated GFR in African American individuals more so than non-African Americans. Evidence Rating Level: 2 (Good) Glomerular filtration rate (GFR), an integral component of establishing drug dosing, prognosis, and treatment of patients with kidney...

1. In a systematic review and meta-analysis of the use of group II (low risk) gadolinium-based contrast agents (GBCA) for MRI in patients with stage 4 and 5 chronic kidney disease (CKD), there were no reported cases of nephrogenic systemic fibrosis (NSF). 2. The use of gadobenate dimeglumine, which is...

1. In a systematic review and meta-analysis of the use of group II (low risk) gadolinium-based contrast agents (GBCA) for MRI in patients with stage 4 and 5 chronic kidney disease (CKD), there were no reported cases of nephrogenic systemic fibrosis (NSF). 2. The use of gadobenate dimeglumine, which is...

1. Potassium binder therapy with patiromer can promote longer duration of spironolactone use for resistant hypertension in the setting of chronic kidney disease. Evidence Rating Level: 1 (Excellent) Spironolactone is recommended in the treatment of resistant hypertension, however there is limited data regarding its use in the setting of chronic kidney...

Fetal nephrogenesis is most significant in the third trimester of pregnancy, and is interrupted by preterm birth before 37 weeks of gestation, resulting in lower nephron numbers and the development of hypertension and progressive renal disease later in life. While low birth weight has been associated with chronic kidney...